Statement of Principles concerning bronchiectasis (Reasonable Hypothesis) (No. 30 of 2017)

This instrument, the Repatriation Medical Authority Statement of Principles concerning bronchiectasis (Reasonable Hypothesis) (No. 30 of 2017), establishes the medical‑causation framework the Authority has determined for linking bronchiectasis, and death from bronchiectasis, to relevant service under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). The instrument is made under subsection 196B(2) of the VEA (s 3) and commences 22 May 2017 (s 2). It expressly revokes the prior Statement of Principles concerning bronchiectasis No. 17 of 2009 (s 4).

Mechanically, the instrument does three things. First, it defines the meaning of bronchiectasis for the purpose of claims under the VEA and MRCA, including express exclusions for congenital bronchiectasis and bronchiectasis associated with several named genetic conditions (s 7(2)(a)-(b)). Second, it lists the discrete factors which, if present and related to a person’s relevant service, are sufficient to raise a "reasonable hypothesis" connecting bronchiectasis or death from bronchiectasis with that service (s 9). Those factors are specified with temporal windows in many instances (for example, within ten years before clinical onset; within five years; within two years; within one year; or "at the time of the clinical onset" or "clinical worsening") and include infectious, inflammatory, obstructive, toxic and occupational causes, immunosuppression and inability to obtain appropriate clinical management (s 9(1)-(45)). Third, it prescribes how those factors relate to service: all listed factors must be related to the person's relevant service (s 10(1)), and the factors in subsections 9(23) to 9(45) are limited to material contribution to, or aggravation of, bronchiectasis where the person’s bronchiectasis was suffered or contracted before or during (but did not arise out of) relevant service (s 10(2)). The instrument also instructs that where a listed factor refers to an injury or disease covered by another Statement of Principles, the factors in that other Statement apply according to its terms (s 11).

The instrument contains a Schedule 1 - Dictionary (s 6, Schedule 1) that defines terms used in the Statement, lists the specified chemical agents, occupational lung diseases and connective tissue diseases that appear in s 9, and supplies clinical definitions or exposure thresholds required to apply particular factors (for example, the arsenic drinking water and clinical evidence thresholds, and the numerical FEV1 threshold and symptom criteria used to define "severe and persistent asthma").

The practical legal effect for a claim under the VEA or MRCA is that decision‑makers will assess whether one or more of the listed factors (with the applicable timing and definitions) existed, and whether those factors are related to the person’s relevant service, in order to determine whether a reasonable hypothesis has been raised. The Statement itself frames that outcome as founded on the Repatriation Medical Authority’s view that there is "sound medical‑scientific evidence" supporting a connection between bronchiectasis and relevant service (s 8). The instrument does not create penalties, provide adjudicative remedies, or set procedural steps; it is an evidentiary/medical standard intended for use in claims under s 120A of the VEA and s 338 of the MRCA (s 5).

This Statement of Principles is organised around a small set of legal-medical concepts that determine when bronchiectasis or death from bronchiectasis can be connected to relevant service. The primary concepts are: the defined disease, the list of qualifying factors, temporal relationships (clinical onset versus clinical worsening), the relationship to relevant service, exclusion and cross-reference to other Statements, and the definitions in Schedule 1 which operationalise many of the factors.

Defined disease. The instrument defines bronchiectasis as "an acquired lung disease with permanent and irreversible, abnormal dilatation of bronchi and bronchioles" and expressly excludes congenital bronchiectasis and bronchiectasis associated with cystic fibrosis, alpha-1-antitrypsin deficiency, common variable immune deficiency and other genetic disorders (s 7(2)). Death from bronchiectasis includes death from a terminal event or condition that was contributed to by the person's bronchiectasis (s 7(3)), where "terminal event" is then defined in the Schedule to include pneumonia, respiratory failure, cardiac arrest, circulatory failure or cessation of brain function.

Reasonable hypothesis and factors. Section 9 lists 45 alternative factors, of which at least one must exist to raise a reasonable hypothesis connecting bronchiectasis or death from bronchiectasis to service. The factors encompass prior infectious lung disease (viral or bacterial pneumonia, pertussis, pulmonary tuberculosis, non‑tuberculous mycobacterial infection), inflammatory diseases (sarcoidosis of the lung), structural causes (bronchial obstruction), specific inhalational chemical exposures from a defined list (s 9(6), Schedule 1 defined list), occupational lung diseases from a specified list, sulphur mustard exposure, aspiration pneumonitis, gastro‑oesophageal reflux disease with erosive oesophagitis or stricture, allergic bronchopulmonary aspergillosis, transplantation, fibrosis or fibrosing interstitial lung disease involving the affected lung segment, arsenic exposure (per the Schedule thresholds), certain connective tissue diseases (specified list), HIV infection, haematalogical malignancy, recent treatment with immunosuppressive drugs (defined in the Schedule), human T‑cell lymphotropic virus type 1 infection, inflammatory bowel disease, severe and persistent asthma (defined in Schedule 1 by FEV1 and symptom criteria), chronic obstructive pulmonary disease, and inability to obtain appropriate clinical management for bronchiectasis (s 9(1)-(45)).

Temporal structure: clinical onset versus clinical worsening. Many factors are expressed with a temporal window before "clinical onset" (for example, pneumonia within ten years before clinical onset in s 9(1); inhalation of specified chemical agents within five years before clinical onset in s 9(6); gastro‑oesophageal reflux disease within two years before clinical onset in s 9(10)). A second block of factors, s 9(23) to 9(45), mirror many earlier factors but are explicitly tied to "clinical worsening" and are subject to the limitation in s 10(2) that they apply only to material contribution to, or aggravation of, bronchiectasis where the bronchiectasis pre‑existed or was contracted before or during (but did not arise out of) relevant service.

The instrument expressly applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). Those statutory references identify the claim frameworks through which veterans, members of Peacekeeping Forces, and members of the Forces may seek compensation or entitlements under the VEA or MRCA. The document also defines "relevant service" in the Schedule (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA; warlike and non‑warlike service under the MRCA), which sets the universe of service that can be the subject of connection to the listed factors (Schedule 1 definition of relevant service). Therefore the primary groups affected are:

• claimants (veterans, current or former members of the Forces) seeking to have bronchiectasis, or death from bronchiectasis, recognised as related to their relevant service under the VEA or MRCA; and

• decision‑makers who assess those claims under the VEA and MRCA, because the Statement supplies the Authority's medical causation framework and the list of factors that raise a reasonable hypothesis (s 3, s 5, s 8).

Other affected parties include treating clinicians, record‑keepers and agencies responsible for service exposure records. The Statement sets out clinically defined criteria and exposure thresholds that require documentary or clinical evidence (for example, radiological confirmation of bronchiectasis, clinical or radiological evidence for aspiration pneumonitis, documented diagnosis of pulmonary tuberculosis, results showing FEV1 60% or less for severe asthma, records of drinking water arsenic concentration, or documentation of exposure to specified chemical agents). Those sorts of records are typically held by treating hospitals, general practitioners, military health services and, for service‑related exposures, Defence or other government agencies responsible for recording exposures. Thus providers who diagnose or treat lung disease in veterans will be indirectly affected because their clinical documentation is the evidentiary basis for claims.

Certain private actors are also implicated by specific factors. Employers, especially those in industries with recognised occupational lung diseases listed in the Schedule (asbestosis, byssinosis, coal worker’s pneumoconiosis, extrinsic allergic alveolitis, flavour worker's lung, hard metal pneumoconiosis, silicosis), may see claims where historical workplace exposures during relevant service are litigated. For claimants asserting arsenic exposure, public utilities or long‑running municipal water records may be material because the Schedule sets a measurable drinking water threshold (average arsenic concentration of at least 50 micrograms per litre for at least ten cumulative years). Where the factor is inability to obtain appropriate clinical management (s 9(45)), health system performance and access to care become directly relevant to claims.

The Statement is not framed as creating criminal duties or rights in the traditional sense; rather, it establishes medical causation criteria that decision‑makers must use when determining whether a "reasonable hypothesis" connects bronchiectasis, or death from bronchiectasis, to relevant service in claims falling under s 120A of the VEA or s 338 of the MRCA (s 5, s 3). The Statement therefore imposes practical duties on officials and rights for claimants in the following ways.

Duties on decision‑makers and assessors. The Repatriation Medical Authority has determined this Statement under subsection 196B(2) of the VEA (s 3), which signals that the Authority’s view is the applicable Statement of Principles for the disease. Decision‑makers assessing claims under the VEA and MRCA must take into account the factors listed in s 9 and the Schedule definitions when deciding whether a reasonable hypothesis has been raised. Section 11 further requires decision‑makers to apply, in accordance with their terms, the factors in any other Statement of Principles that is referred to by a factor in this Statement. Section 10(1) requires decision‑makers to establish that any factor relied on is related to the person’s relevant service. Section 10(2) places a further constraint on the use of subsections 9(23)-9(45), limiting their application to material contribution to or aggravation of bronchiectasis that was suffered or contracted before or during (but did not arise out of) relevant service.

Rights and evidential thresholds for claimants. The instrument identifies a discrete set of circumstances that, if proved and related to relevant service, suffice to raise a reasonable hypothesis; that is a legal evidentiary threshold used in the statutory claims process. For claimants, this creates a pathway: establishing that one or more of the listed factors existed (and satisfies the temporal tests and definitions in the Schedule), and demonstrating its relation to relevant service, will meet the Authority’s test for a reasonable hypothesis. The instrument supplies the specific medical and exposure tests claimants must address: for example, evidence of viral or bacterial pneumonia within ten years before clinical onset (s 9(1)); evidence of inhalation of specified chemical agents producing severe acute lower respiratory damage with persistent respiratory symptoms for at least one week within five years before onset (s 9(6)); or evidence of chronic arsenic exposure quantified by drinking water at or above a 50 micrograms per litre average for ten cumulative years (Schedule definition of being exposed to arsenic as specified).

This Statement of Principles does not itself create offences, fines or criminal penalties, nor does it prescribe administrative sanctions. The instrument is an evidentiary standard and medical‑causation framework for the purpose of claims under the VEA and MRCA, made under subsection 196B(2) of the VEA (s 3), and applies to claims falling under the statutory claim provisions referred to in s 5. The text contains no section that imposes enforcement powers, investigative authority or disciplinary measures.

Enforcement and application occur through the claims adjudication process under the VEA and MRCA. The Statement is intended to be applied by the relevant decision‑makers who determine entitlement under s 120A of the VEA or s 338 of the MRCA (s 5). Those decision‑makers use the Statement as the Repatriation Medical Authority’s determination of the medical factors that raise a reasonable hypothesis. The instrument itself does not identify the precise procedural steps decision‑makers must follow; those are set by the parent statutes and administrative rules outside the text of this instrument.

Practical enforcement consequences. Because the Statement sets the medical evidence that raises a reasonable hypothesis, its practical effect in enforcement is that a claimant who can demonstrate the presence of a listed factor, within the stated temporal window and related to relevant service (s 10), should meet the Authority’s threshold for medically linking bronchiectasis or death from bronchiectasis to service. Conversely, absence of any listed factor or inability to establish a service relationship will weaken or defeat a claim under the frameworks to which this Statement applies. The Statement therefore functions as a quasi‑binding matrix that determines which medical facts count for or against a claimant, and it will shape the outcomes of claims and any appeals of those decisions conducted under the parent statutes.

No investigatory powers included. The Statement does not authorise new investigatory tools or compel third parties to produce evidence. It is silent on evidentiary procedures, burden of proof beyond the "reasonable hypothesis" test implicit in the statutory scheme, or the allocation of legal costs. Any compulsion to obtain evidence must therefore derive from the parent statutes or from the ordinary powers of the decision‑making bodies and courts, not from this instrument itself.

Revocation and transitional effect. The Statement revokes the earlier Statement concerning bronchiectasis No. 17 of 2009 (s 4), which alters the forensic landscape for claims assessed after commencement. The instrument does not include transitional enforcement clauses; it therefore falls to the administering authorities to apply the current Statement in appropriate claims processes, and to manage any claims that span the revocation date according to the governing statutory procedures.

The instrument situates itself within the statutory framework of veterans’ entitlements and compensation by reference to the VEA and MRCA. It is made under subsection 196B(2) of the VEA (s 3) and expressly applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). Those cross‑references are the primary statutory touchpoints and imply that the Statement’s medical factors will be applied within the adjudicative, procedural and remedial frameworks of those statutes.

Interaction with other Statements of Principles. Section 11 creates a direct inter‑instrument interaction rule: where a factor in this Statement refers to an injury or disease that has its own Statement of Principles determined under subsection 196B(2) of the VEA, then the factors in that other Statement "apply in accordance with the terms of that Statement of Principles as in force from time to time." That means practitioners must cross‑check s 9 factors that reference other conditions against those other Statements. For example, where s 9 refers to "an occupational lung disease from the specified list" and those diseases may themselves be the subject of separate Statements, the decision‑maker must apply the other Statement’s factors when assessing that component of the case.

Relationship to the VEA and MRCA claim frameworks. The instrument does not repeat the procedures, remedies or appeals frameworks contained in the VEA or MRCA. Its role is to provide the Repatriation Medical Authority’s medical causation determinations for the specific disease. The Statement therefore interfaces with procedural law by supplying the medical tests and definitions that the administering agencies and tribunals will apply when resolving entitlement under the parent statutes. Because the instrument applies to claims "to which section 120A of the VEA or section 338 of the MRCA applies" (s 5), the statutes’ definitions of how a "reasonable hypothesis" is used in claims resolution will govern the legal weight of the Statement, but those statutory provisions are not reproduced in the instrument.

Revocation of earlier Statement and continuity. Section 4 revokes the Statement of Principles concerning bronchiectasis No. 17 of 2009. That revocation alters the legal instruments available to decision‑makers and claimants. Where the old Statement had different factors, definitions or temporal tests, the applicable medical test for claims will now be this 2017 Statement. The instrument does not provide transitional provisions; application of the new Statement versus the old will therefore be governed by the parent legislation and administrative practice.

The instrument itself provides a compact amendment history in its key operative provisions; no other amendments or versions are contained within the text provided. The facts set out in the instrument that relate to amendment history are:

• This is the Statement of Principles concerning bronchiectasis (Reasonable Hypothesis) (No. 30 of 2017) (s 1).

• The instrument is dated 21 April 2017 (front page) and commences on 22 May 2017 (s 2).

• It was made under subsection 196B(2) of the VEA (s 3), and bears the seal and signature directions of the Repatriation Medical Authority (front page imprint and Chairperson signature).

• Section 4 revokes the Statement of Principles concerning bronchiectasis No. 17 of 2009 made under subsection 196B(2) of the VEA.

From the document alone, the amendment history therefore consists of a replacement: the 2017 Statement supersedes the 2009 Statement on commencement. The instrument provides no further detail about the content differences between the 2009 and 2017 Statements, nor about the administrative process leading to the revision. It also does not include transitional provisions, savings clauses or retrospective application language in the text provided.

Implications of the single revocation contained in the instrument. The revocation in s 4 means that decisions made after the commencement date must be assessed against the 2017 Statement rather than the 2009 Statement. Because the instrument does not include transitional rules, whether a claim that spans the revocation date is assessed under the new or old Statement will depend on the governing provisions in the VEA and MRCA and applicable administrative practice, which are outside this instrument. Practitioners must therefore be alert to the commencement date (22 May 2017) and the fact that the 2009 Statement has been revoked; when advising clients or preparing claims, the current Statement is 2017 No. 30.

No subsequent amendments are recorded in the instrument. The document contains no schedules indicating later amendments, no footnotes or marginal notes indicating changes post‑2017, and no reference to future review dates. If later amendments to the Statement of Principles were made, they are not present in the text supplied. Accordingly, any practitioner needing to know whether later changes exist must consult the statutory register or the Repatriation Medical Authority’s official repository beyond this document.

No internal amendment history details. The instrument does not include an explanatory memorandum, second reading speech text, or regulatory impact statement within the provided file. It therefore does not reveal the RMA’s internal reasons for each change relative to the 2009 Statement, nor the scientific studies that prompted revision. The only assertion about the evidentiary basis is the Authority’s statement that "there is sound medical‑scientific evidence" indicating bronchiectasis and death from bronchiectasis can be related to relevant service (s 8), but the instrument does not append or summarise that evidence.

The instrument itself contains no litigation history, case citations or judicial interpretations. It does not list any appeals, tribunal decisions, or court rulings that have interpreted this Statement of Principles, and it names no cases. The single legal history item recorded in the instrument is administrative: the revocation of the earlier Statement of Principles concerning bronchiectasis No. 17 of 2009 (s 4) and the making of the present Statement under subsection 196B(2) of the VEA (s 3).

Because the Statement is an administrative medical determination intended for use in claims under the VEA and MRCA (s 5), disputes about its application are likely to arise in the statutory adjudicative processes specified in those Acts, but the instrument does not describe those processes or any litigation outcomes. The instrument does not purport to be a judicial document, and it contains no annotations indicating that any part of it has been subject to judicial review or that its factors have been judicially scrutinised.

Practical consequence for practitioners. In the absence of any litigation history in the text, those advising claimants or respondents must not rely on judicial gloss from this instrument alone. Where legal arguments about interpretation, the meaning of "reasonable hypothesis", or the application of particular factors are required, practitioners will need to seek decisions of the Veterans' Review Board, the Administrative Appeals Tribunal, the Veterans' Review Boards, Federal Court or other tribunals and courts that have considered claims under the VEA and MRCA. The instrument itself provides no such decision law.

Limits on drawing inferences. Because no cases are named and no outcomes recorded in the instrument, it is not possible from the text alone to infer how strictly tribunals or courts will interpret the temporal windows (for example, the significance of "within ten years before clinical onset") or how evidentiary burdens are applied in practice when claimants assert exposures like arsenic contaminated drinking water or inhalation of specified chemical agents. Similarly, the document does not provide examples or illustrations of fact patterns that met or failed to meet the reasonable hypothesis threshold.

Where to look for litigation. To establish litigation history, practitioners must consult external sources: published decisions of veterans’ review bodies and courts, tribunal determinations relating to bronchiectasis claims that reference this Statement of Principles, and any later administrative rulings. Those external decisions will reveal how decision‑makers treat the Statement, how they apply the Schedule definitions, and how they resolve disputes about the service relationship required by s 10(1) and the limitations in s 10(2) relating to aggravation.

This Statement contains several provisions that create practical pitfalls for claimants, clinicians and advisers if they are not closely attended to. The following are concrete "gotchas" grounded in the instrument text and the definitions in the Schedule.

1. Distinction between clinical onset and clinical worsening; two separate factor blocks. Many factors require occurrence "within X years before the clinical onset" (see s 9(1)-(22)) while another set of factors mirror those but apply to "clinical worsening" (s 9(23)-(45)). Section 10(2) then limits subsections 9(23)-(45) to cases where the claimant’s bronchiectasis was suffered or contracted before or during (but did not arise out of) relevant service. The practical effect is that the legal test for an initial causal connection differs from the test for material contribution/aggravation; advisers must carefully establish whether the claim is for initial causation or for aggravation to know which provisions apply.

2. Exclusions for congenital and genetic disorders. The definition of bronchiectasis excludes congenital bronchiectasis and bronchiectasis associated with cystic fibrosis, alpha‑1‑antitrypsin deficiency, common variable immune deficiency and other genetic disorders (s 7(2)(b)). If a claimant’s bronchiectasis is congenital or associated with these genetic conditions, this Statement is not the correct instrument. Practitioners must establish whether the bronchiectasis is acquired and not attributable to the excluded genetic causes.

3. Temporal windows require precise dating. The instrument uses multiple different temporal windows: ten years (pneumonia, pertussis), five years (specified chemical agents, occupational lung disease exposure, aspiration pneumonitis, immunosuppression queries), two years (gastro‑oesophageal reflux disease with erosive oesophagitis or stricture), and one year (acute lower respiratory infection before clinical worsening). Failure to provide documentary or clinical evidence within the applicable window will likely be fatal to relying on that factor. Claimants should not presume that any past infection suffices; the timing requirement is explicit.

4. Specified chemical agents require both acute severity and persistence. The chemical agent factor in s 9(6) and s 9(28) is not satisfied simply by exposure. Two further medical requirements are set: (a) the exposure must have resulted in signs and symptoms of severe acute lower respiratory damage requiring medical attention within 48 hours after exposure, and (b) respiratory symptoms and signs must have persisted for at least one week after exposure. Both elements must be met within the five years before clinical onset or clinical worsening. A claim that relies on inhalation of, say, chlorine, but lacks contemporaneous medical records documenting severe acute lower respiratory damage and subsequent persistence of symptoms for a week will fail to meet the stated factor.

Compliance in this context means preparing and presenting a claim under the VEA or MRCA that aligns with the factors, definitions and temporal tests set out in this Statement so as to raise a reasonable hypothesis relating bronchiectasis or death from bronchiectasis to relevant service. The following steps translate the instrument’s provisions into practical actions for claimants, clinicians, advisers and decision‑makers.

1. Establish the correct statutory pathway. Confirm that the claim falls within a statutory framework to which this Statement applies: claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). If the claim lies outside those provisions, this Statement may not govern causation.

2. Determine whether the bronchiectasis falls within the Statement’s definition. Verify that the claimant’s bronchiectasis is acquired, permanent and irreversible, and involves abnormal dilatation of bronchi and bronchioles (s 7(2)(a)). Exclude congenital bronchiectasis and bronchiectasis associated with cystic fibrosis, alpha‑1‑antitrypsin deficiency, common variable immune deficiency or other genetic disorders (s 7(2)(b)), by obtaining genetic tests, early childhood medical history, or specialist reports as needed.

3. Decide whether the claim is for initial causation or for material contribution/aggravation. If the claimant’s bronchiectasis arose before or during but not out of relevant service, and the present claim is for worsening, then subsections 9(23)-9(45) and s 10(2) are applicable. If the claim is for initial causation, use subsections 9(1)-9(22). The classification determines which factors and temporal windows to address.

4. Identify at least one qualifying factor and gather supporting evidence. Review the 45 listed factors in s 9 and the Schedule definitions. For any selected factor, compile contemporaneous medical records, specialist reports, imaging, laboratory results and exposure records that satisfy the factor’s specific test:

   • For infectious antecedents (s 9(1), 9(2), 9(3), etc.), assemble hospital records, microbiology/laboratory reports, chest imaging and discharge summaries with dates to meet the temporal windows (for example, pneumonia within ten years before clinical onset).

   • For inhalational chemical exposures (s 9(6), s 9(28)), obtain immediate post‑exposure records documenting severe acute lower respiratory damage requiring medical attention within 48 hours and records showing persistence of symptoms for at least one week, along with documented timing within five years of onset/worsening.